DIAGNOS Inc. (ADK.V)
| Previous Close | 0.3300 |
| Open | 0.3250 |
| Bid | 0.3400 x 0 |
| Ask | 0.3450 x 0 |
| Day's Range | 0.3250 - 0.3450 |
| 52 Week Range | 0.2800 - 0.6700 |
| Volume | |
| Avg. Volume | 111,500 |
| Market Cap | 23.846M |
| Beta (5Y Monthly) | 0.06 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0370 |
| Earnings Date | Oct. 27, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.55 |
- GlobeNewswire
DIAGNOS Provides Corporate Update for 2021 and Outlook for 2022
BROSSARD, Quebec, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Company”) (TSX Venture: ADK) (OTCQB: DGNOF), a leader in early detection of critical health issues based on Artificial Intelligence, is pleased to provide a corporate update on its major activities from 2021 operations. DIAGNOS would like to share some of the highlights and successes achieved this past year and also provide some insight into what we are working on for the upcoming year. Although COVID has present
- GlobeNewswire
DIAGNOS will be Attending in San Francisco during the J.P. Morgan Health Care Conference Week to be held from January 10th to 13th, 2022
BROSSARD, Quebec, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Company”) (TSX Venture: ADK) (OTCQB: DGNOF), a leader in early detection of critical health issues, announces today that DIAGNOS will be in San Francisco during the J.P. Morgan 40th Annual Healthcare Conference events running from January 10th to 13th, 2022 in San Francisco, California. Forty years ago, J.P. Morgan launched Wall Street’s premier investor conference focused exclusively on companies defining the he
- GlobeNewswire
DIAGNOS will start a clinical trial study in the USA commencing December 6th, 2021 for early detection and prevention of Stroke using CARA-STROKE.
BROSSARD, Quebec, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Company”) (TSX Venture: ADK) (OTCQB: DGNOF), a leader in early detection of critical health issues, announces today the beginning of a clinical trial study with CommonSpirit Health Research Institute, Chattanooga Center for Neurologic Research LLC and conducted at the CommonSpirit Hospital in Chattanooga, to confirm early Proof-of-Concept results that showed a strong potential in the early detection of stroke thr
